FI961681A0 - Combination of bisphosphonate and plant hormone secretion increasing substances - Google Patents
Combination of bisphosphonate and plant hormone secretion increasing substancesInfo
- Publication number
- FI961681A0 FI961681A0 FI961681A FI961681A FI961681A0 FI 961681 A0 FI961681 A0 FI 961681A0 FI 961681 A FI961681 A FI 961681A FI 961681 A FI961681 A FI 961681A FI 961681 A0 FI961681 A0 FI 961681A0
- Authority
- FI
- Finland
- Prior art keywords
- bisphosphonate
- combination
- hormone secretion
- plant hormone
- increasing substances
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13929693A | 1993-10-19 | 1993-10-19 | |
US25909194A | 1994-06-13 | 1994-06-13 | |
PCT/US1994/011912 WO1995011029A1 (en) | 1993-10-19 | 1994-10-18 | Combination of bisphosphonates and growth hormone secretagogues |
Publications (2)
Publication Number | Publication Date |
---|---|
FI961681A0 true FI961681A0 (en) | 1996-04-17 |
FI961681A FI961681A (en) | 1996-06-12 |
Family
ID=26837073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI961681A FI961681A (en) | 1993-10-19 | 1996-04-17 | A combination of bisphosphonates and growth hormone secretagogues |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0813414A4 (en) |
JP (1) | JPH09504525A (en) |
KR (1) | KR960705575A (en) |
CN (1) | CN1136278A (en) |
AU (1) | AU8083694A (en) |
BG (1) | BG100517A (en) |
BR (1) | BR9407869A (en) |
CA (1) | CA2173333A1 (en) |
CZ (1) | CZ109196A3 (en) |
FI (1) | FI961681A (en) |
HU (1) | HUT75224A (en) |
LV (1) | LV11432B (en) |
NO (1) | NO961536L (en) |
PL (1) | PL314003A1 (en) |
SK (1) | SK49796A3 (en) |
WO (1) | WO1995011029A1 (en) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5686624A (en) * | 1992-01-30 | 1997-11-11 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
US20020111461A1 (en) | 1999-05-21 | 2002-08-15 | Todd C. Somers | Low molecular weight peptidomimetic growth hormone secretagogues |
US5798337A (en) * | 1994-11-16 | 1998-08-25 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
JP3133073B2 (en) * | 1995-05-29 | 2001-02-05 | ファイザー・インコーポレーテッド | Dipeptides that stimulate growth hormone release |
JPH11513989A (en) * | 1995-10-27 | 1999-11-30 | メルク エンド カンパニー インコーポレーテッド | Wet granulation of growth hormone secretagogue |
WO1997022004A1 (en) | 1995-12-13 | 1997-06-19 | Merck & Co., Inc. | Assays for growth hormone secretagogue receptors |
US6531314B1 (en) | 1996-12-10 | 2003-03-11 | Merck & Co., Inc. | Growth hormone secretagogue receptor family |
TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
HN1996000101A (en) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | COMBINED THERAPY FOR OSTEOPOROSIS |
BR9709499A (en) * | 1996-05-31 | 1999-08-10 | Novo Nordisk As | Process for preventing or treating osteoporosis and related disorders using a growth hormone component using a composition with an anti-resorptive action on bones and products |
AU4993497A (en) * | 1996-10-25 | 1998-05-22 | Merck & Co., Inc. | Convergent process for the preparation of a growth hormone secretagogue |
US6376477B2 (en) | 1996-11-25 | 2002-04-23 | Merck & Co., Inc. | Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism |
GB2324726A (en) * | 1997-05-01 | 1998-11-04 | Merck & Co Inc | Combination Therapy for the Treatment of Osteoporosis |
ZA987385B (en) * | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
US6211174B1 (en) * | 1997-10-31 | 2001-04-03 | Merck & Co., Inc. | Naphtho-fused lactams promote release of growth hormone |
IT1296495B1 (en) * | 1997-11-21 | 1999-06-25 | Prodotti Antibiotici Spa | USE OF BISPHOSPHONATES IN THE PREPARATION OF PHARMACEUTICAL FORMS FOR INTRAMUSCULAR ADMINISTRATION |
US6682908B1 (en) | 1998-07-10 | 2004-01-27 | Merck & Co., Inc. | Mouse growth hormone secretagogue receptor |
CA2333857A1 (en) | 1998-07-13 | 2000-01-20 | Merck & Co., Inc. | Growth hormone secretagogue related receptors and nucleic acids |
JP2002522058A (en) | 1998-08-10 | 2002-07-23 | メルク・アンド・カンパニー・インコーポレーテッド | Canine growth hormone secretagogue receptor |
EP1112071A4 (en) * | 1998-08-18 | 2003-03-19 | Lilly Co Eli | Growth hormone secretagogues |
US6639076B1 (en) | 1998-08-18 | 2003-10-28 | Eli Lilly And Company | Growth hormone secretagogues |
AR013994A1 (en) * | 1998-10-30 | 2001-01-31 | Gador Sa | PROCEDURE AND PREPARATIONS THAT SELECTIVELY MODULATE THE FUNCTION OF THE OSTEOBLASTO FOR THE PREVENTION AND TREATMENT OF FRAGILIZING OSTEOPATHIES. |
US6416737B1 (en) * | 1998-11-19 | 2002-07-09 | Board Of Trustees Of The University Of Arkansas | Increasing bone strength with selected bisphosphonates |
US6828331B1 (en) | 1999-02-19 | 2004-12-07 | Eli Lilly And Company | Growth hormone secretagogues |
CN1372468A (en) * | 1999-06-02 | 2002-10-02 | 宝洁公司 | Oral preparations of etidronate disodium |
ATE446758T1 (en) | 2000-05-31 | 2009-11-15 | Pfizer Prod Inc | USE OF GROWTH HORMONE SECRETAGOGENES TO PROMOTE DIGESTIVE MOTILITY |
US6548042B2 (en) | 2000-08-07 | 2003-04-15 | Arstad Erik | Bis-phosphonate compounds |
WO2002058708A1 (en) | 2001-01-23 | 2002-08-01 | Gador S.A. | Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof |
US7125840B2 (en) | 2001-10-09 | 2006-10-24 | Eli Lilly And Company | Substituted dipeptides as growth hormone secretagogues |
US7396846B2 (en) | 2002-04-09 | 2008-07-08 | Eli Lilly And Company | Growth hormone secretagogues |
GB0213715D0 (en) | 2002-06-14 | 2002-07-24 | Syngenta Ltd | Chemical compounds |
JP4861817B2 (en) * | 2003-05-07 | 2012-01-25 | オステオロジックス エイ/エス | Combination treatment with strontium for the prevention and / or treatment of cartilage and / or bone symptoms |
US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
US7786141B2 (en) | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
MX2007002033A (en) | 2004-08-19 | 2007-04-26 | Vertex Pharma | Modulators of muscarinic receptors. |
KR20070086756A (en) | 2004-11-29 | 2007-08-27 | 버텍스 파마슈티칼스 인코포레이티드 | Modulators of muscarinic receptors |
EP1973543A2 (en) | 2005-12-22 | 2008-10-01 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
CA2642649A1 (en) | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
JP2009527568A (en) | 2006-02-22 | 2009-07-30 | バーテックス ファーマシューティカルズ インコーポレイテッド | Modulator of muscarinic receptor |
CU23558A1 (en) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE |
CN101500565A (en) | 2006-06-29 | 2009-08-05 | 弗特克斯药品有限公司 | Modulators of muscarinic receptors |
CN101553231A (en) | 2006-08-15 | 2009-10-07 | 弗特克斯药品有限公司 | Modulators of muscarinic receptors |
CA2660974A1 (en) | 2006-08-18 | 2008-02-21 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
MX2009008574A (en) | 2007-02-09 | 2009-12-09 | Tranzyme Pharma Inc | Macrocyclic ghrelin receptor modulators and methods of using the same. |
EP2155769B1 (en) | 2007-05-04 | 2012-06-27 | Katholieke Universiteit Leuven KU Leuven Research & Development | Tissue degeneration protection |
MX2010003373A (en) | 2007-10-03 | 2010-04-30 | Vertex Pharma | Modulators of muscarinic receptors. |
WO2013190520A2 (en) | 2012-06-22 | 2013-12-27 | The General Hospital Corporation | Gh-releasing agents in the treatment of vascular stenosis and associated conditions |
JP6649902B2 (en) | 2014-05-30 | 2020-02-19 | ファイザー・インク | Carbonitrile derivatives as selective androgen receptor modulators |
CN112399860A (en) | 2018-06-06 | 2021-02-23 | 麻省理工学院 | Circular RNA for translation in eukaryotic cells |
IL310266A (en) | 2019-05-22 | 2024-03-01 | Massachusetts Inst Technology | Circular rna compositions and methods |
EP4289951A3 (en) | 2019-12-04 | 2024-03-13 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU569391B2 (en) * | 1984-04-30 | 1988-01-28 | Procter & Gamble Company, The | Treating osteoporosis |
DE3514583A1 (en) * | 1984-04-30 | 1985-10-31 | The Procter & Gamble Co., Cincinnati, Ohio | Use of a two-phase or multiphase composition for the treatment or prevention of osteoporosis |
RO115804B1 (en) * | 1992-12-11 | 2000-06-30 | Merck & Co Inc | Spiropyperidine derivatives, processes for preparation and pharmaceutical compositions thereof |
US5284841A (en) * | 1993-02-04 | 1994-02-08 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
US5434261A (en) * | 1993-07-26 | 1995-07-18 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
US5545735A (en) * | 1993-10-04 | 1996-08-13 | Merck & Co., Inc. | Benzo-Fused Lactams promote release of growth hormone |
-
1994
- 1994-10-18 CA CA002173333A patent/CA2173333A1/en not_active Abandoned
- 1994-10-18 BR BR9407869A patent/BR9407869A/en not_active Application Discontinuation
- 1994-10-18 CN CN94194311A patent/CN1136278A/en active Pending
- 1994-10-18 SK SK497-96A patent/SK49796A3/en unknown
- 1994-10-18 KR KR1019960702007A patent/KR960705575A/en not_active Application Discontinuation
- 1994-10-18 EP EP94931923A patent/EP0813414A4/en not_active Withdrawn
- 1994-10-18 AU AU80836/94A patent/AU8083694A/en not_active Abandoned
- 1994-10-18 JP JP7512182A patent/JPH09504525A/en active Pending
- 1994-10-18 HU HU9601013A patent/HUT75224A/en unknown
- 1994-10-18 WO PCT/US1994/011912 patent/WO1995011029A1/en not_active Application Discontinuation
- 1994-10-18 CZ CZ961091A patent/CZ109196A3/en unknown
- 1994-10-18 PL PL94314003A patent/PL314003A1/en unknown
-
1996
- 1996-04-17 FI FI961681A patent/FI961681A/en unknown
- 1996-04-18 NO NO961536A patent/NO961536L/en unknown
- 1996-04-18 BG BG100517A patent/BG100517A/en unknown
- 1996-04-23 LV LVP-96-124A patent/LV11432B/en unknown
Also Published As
Publication number | Publication date |
---|---|
LV11432A (en) | 1996-08-20 |
CZ109196A3 (en) | 1996-10-16 |
SK49796A3 (en) | 1997-05-07 |
HUT75224A (en) | 1997-04-28 |
LV11432B (en) | 1996-12-20 |
EP0813414A4 (en) | 1999-07-21 |
JPH09504525A (en) | 1997-05-06 |
NO961536L (en) | 1996-06-18 |
AU8083694A (en) | 1995-05-08 |
CN1136278A (en) | 1996-11-20 |
HU9601013D0 (en) | 1996-06-28 |
NO961536D0 (en) | 1996-04-18 |
BG100517A (en) | 1996-11-29 |
BR9407869A (en) | 1996-10-29 |
PL314003A1 (en) | 1996-08-05 |
KR960705575A (en) | 1996-11-08 |
FI961681A (en) | 1996-06-12 |
EP0813414A1 (en) | 1997-12-29 |
WO1995011029A1 (en) | 1995-04-27 |
CA2173333A1 (en) | 1995-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI961681A0 (en) | Combination of bisphosphonate and plant hormone secretion increasing substances | |
FI932960A0 (en) | Control of fructors mogning and vaexters foeraoldring | |
FI971969A (en) | Compositions for the treatment of hemorrhoids and method of use | |
SE9301347A0 (en) | Anti-foaming composition of emulsion type and anti-foaming method using the same | |
FI934361A (en) | Foerfarande and anordning Foer evaluato av vaegningsparametrarna Foer en signal i en mottagare | |
FI940509A (en) | Procedure for the manufacture of normal and ultrafine cement | |
FI950128A0 (en) | Automated system and procedure for the treatment of biologically liquid substance | |
BR1100824A (en) | Pharmaceutical composition and composition | |
KR950702313A (en) | Color filter and its material and resin | |
FI88426B (en) | OVER ANCHORING FOR RICTURE OF BORRMASKINS MATARBALK | |
FI923747A (en) | COMPOSITION AND OVERFLOWER FOR BEHANDLING AV INFECTIONAL FOREIGN ORGANISMER SENSITIVE FOR B-LACTAMANTIBIOTICS | |
FI960483A (en) | Changing composition and procedures for its use | |
FI945992A0 (en) | Transport and distribution of varoenheter and fartyg | |
FI931161A0 (en) | COMPOSITION INNEHAOLLANDE ESTRAR AV KARBOXYLHALTIGA INTERPOLYMERER OCH ANVAENDNING AV DESSA | |
FI922139A (en) | OVER ANCHORING OF ANHYDRIT STYGIPS | |
FI933642A (en) | Composition and preparation For the purpose of this Regulation | |
FI935559A0 (en) | Foer farande Foer faestning av haordmetallstift i en borrkrona and en borrkrona | |
FI920758A (en) | COMPOSITION AND DESIGN OF SAOSOM BIOCID | |
FI943213A (en) | Process for the preparation of 3-acyl esters and acylbenzenes | |
FI91347C (en) | Procedure for performing time interval switching and time switching | |
FI912940A (en) | OVER ANCHORING FOER STYRNING AV START AND AV SCREW COMPRESSOR | |
FI934787A (en) | Foerfarande Foer maetning av inverkan av instaellningar vid en inloppslaoda and corrections av ytvikts- och fiberorienteringstvaerprofenen | |
FI970713A (en) | Procedures for maintaining the condition of the teeth and the skeleton | |
FI971378A0 (en) | Methods and intermediates for the preparation of 3-aminobenzo (b) azepinones | |
FI933939A0 (en) | PROCEDURE FOR THE IDENTIFICATION OF THE IDENTIFICATION OF MATERIALS AND MATERIALS |